For the first time, the American Society of Clinical Oncology (ASCO) has published guidelines that address “all aspects of clinical management” related to malignant pleural mesothelioma (Oppenheimer, 2018). They have determined the main form of treatment should be chemotherapy since most patients diagnosed with the disease are beyond the point where cancer can be fully removed surgically. For those with tumors that are able to be surgically removed, ASCO recommends the inclusion of chemotherapy to their treatment, with or without radiation.
Even though there have not been any recent drugs approved for the treatment of mesothelioma, ASCO states that significant advances are being made in understanding the “biology of mesothelioma and identifying new targets for therapy” (Kindler, 2018). ASCO also states that strides are being made in the study of mesothelioma including new treatment options. Ongoing clinical trials are showing promising activity, but “are not sufficiently mature to make treatment recommendations.”
Kindler, H. et all (2018, January 18). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Retrieved February 02, 2018, from http://ascopubs.org/doi/full/10.1200/JCO.2017.76.6394
Oppenheimer, T. (2018, January 31). American Society of Clinical Oncology Releases First-Ever Guidelines for Mesothelioma. Retrieved February 02, 2018, from https://mesothelioma.net/mesothelioma-news/american-society-clinical-oncology-releases-first-ever-guidelines-mesothelioma/